Data from three major Phase 3 trials are expected by the end of the year, including AriBio’s trial of a repurposed erectile dysfunction pill called AR1001, Cognito Therapeutics’ SPECTRIS brain stimulation device, and Bristol-Myers Squibb’s KarXT drug for Alzheimer’s-related agitation and psychosis.